Long-term safety study of axitinib implant for wet macular degeneration
Part of Eyes & vision clinical trials.
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed either the OTX-TKI-2023-AMD-301 study (through week 104) or OTX-TKI-2023-AMD-303 study (through week 96)
- You have wet macular degeneration in the study eye
- Your eye's lens and pupil are clear enough for good quality imaging
- No serious eye infections in the past 3 months
- No history of inflammation inside the eye
- No retinal detachment, macular hole, or other serious retinal problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a follow-up for people who have already received an injection of RGX-314 for wet age-related macular degeneration (AMD) in an earlier trial. It looks at how the treatment works over a longer time and any long-term effects.
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
This study tests an eye implant (OTX-TKI) that slowly releases a medicine to slow or stop worsening of non-proliferative diabetic retinopathy (NPDR) — an early form of diabetic eye disease. It's for people with moderately severe to severe NPDR who haven't had significant treatments like laser or injections in that eye.
This trial tests a new gene therapy called LX109 for wet age-related macular degeneration (nAMD). It is for patients who still need regular anti-VEGF injections, and the treatment aims to reduce how often you need those injections.
This study checks how well a previous eye treatment (RGX-314) lasts over time. There is also an extra “other eye” study for people with age-related macular degeneration affecting both eyes.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.